Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | - | 5.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 1.06 | 1.36 |
NAV | ₹10.35 | ₹200.73 |
Fund Started | 02 Jun 2025 | 07 May 2007 |
Fund Size | ₹179.06 Cr | ₹92168.85 Cr |
Exit Load | Exit load of 0.25%, if redeemed within 15 days. | Exit load of 1% if redeemed within 1 year. |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | - | 3.05% |
3 Year | - | 24.34% |
5 Year | - | 25.62% |
1 Year
3 Year
5 Year
Equity | 100.83% | 93.70% |
Cash | -0.83% | 6.30% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
BSE Ltd. | 3.12% |
Hero Motocorp Ltd. | 2.11% |
Persistent Systems Ltd. | 1.79% |
Suzlon Energy Ltd. | 1.72% |
Coforge Ltd. | 1.68% |
The Federal Bank Ltd. | 1.67% |
PB Fintech Ltd. | 1.61% |
Cummins India Ltd. | 1.59% |
Dixon Technologies (India) Ltd. | 1.57% |
Indusind Bank Ltd. | 1.49% |
Name | Assets |
|---|---|
Max Financial Services Ltd. | 4.76% |
AU Small Finance Bank Ltd. | 4.06% |
The Federal Bank Ltd. | 3.58% |
Indian Bank | 3.48% |
Balkrishna Industries Ltd. | 3.31% |
Coforge Ltd. | 3.23% |
Ipca Laboratories Ltd. | 2.81% |
Fortis Healthcare Ltd. | 2.78% |
Hindustan Petroleum Corporation Ltd. | 2.76% |
Glenmark Pharmaceuticals Ltd. | 2.67% |
Name | Kapil Menon | Chirag Setalvad |
Start Date | 02 Jun 2025 | 28 Jun 2014 |
Name
Start Date
Description | The scheme seeks to provide returns, before expenses, that commensurate with the performance of Nifty Midcap 150 Index (TRI), subject to tracking error. | The scheme seeks to provide long-term capital appreciation/income by investing predominantly in Mid-Cap companies. |
Launch Date | 02 Jun 2025 | 07 May 2007 |
Description
Launch Date